The 2022 Tandem Meetings | The fast-changing field of CAR-T therapy
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, shares his excitement for some of the novel CAR-T products in early clinical development, including allogeneic and bispecific CAR-Ts, as well as CAR-NKs. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Transcript (edited for clarity)
I think I’m just excited by the number of novel approaches that are occurring in CAR-T. In this conference, we’re going to hear about allogeneic products, bispecific products like the work we’re doing. We’re going to hear about NK CAR-T products. And it appears that each product seems to be, at least in these early phase studies, improving efficacy, working in CAR, it’s both populations, and improving the safety profile...
I think I’m just excited by the number of novel approaches that are occurring in CAR-T. In this conference, we’re going to hear about allogeneic products, bispecific products like the work we’re doing. We’re going to hear about NK CAR-T products. And it appears that each product seems to be, at least in these early phase studies, improving efficacy, working in CAR, it’s both populations, and improving the safety profile. Now, none of this is ready for prime time, but I have to tell you, the cell therapy field for B-cell malignancies and hematological malignancies is exploding. And I’m excited to be a part of that process.
Read more...
